Adjuvant systemic therapy in breast carcinoma in the 1990s: status of things and open questions
Goldhirsch, A.; Neuenschwander, H.; Castiglione, M.; Senn, H.J.; Cavalli, F.
Schweizerische Medizinische Wochenschrift 120(47): 1771-1783
1990
ISSN/ISBN: 0036-7672 PMID: 2255883 Document Number: 360313
Adjuvant systemic therapy of breast cancer has been shown to reduce relapses and prolong survival in the women treated. This is true of all subpopulations studied. Six-month multidrug chemotherapy in premenopausal patients, and tamoxifen or short-term chemotherapy in postmenopausal patients, are the treatments of choice in reducing the risk of relapse. In the near future ongoing research may answer some of the open questions surrounding the definition of populations for which the risk of relapse justifies therapy and the optimum manner of using available therapies. The modest but real improvement in prognosis of operable breast cancer was obtained solely by means of clinical trials. Participation in clinical research programs is becoming medically and socially mandatory.